Rates of febrile neutropenia and its causes in the real world.

Autor:	Borgeaud M; Department of Oncology, Geneva University Hospitals, Geneva, 1205, Switzerland., Perano S; Department of Oncology, Geneva University Hospitals, Geneva, 1205, Switzerland., Addeo A; Department of Oncology, Geneva University Hospitals, Geneva, 1205, Switzerland., Tsantoulis P; Department of Oncology, Geneva University Hospitals, Geneva, 1205, Switzerland.
Jazyk:	angličtina
Zdroj:	Future oncology (London, England) [Future Oncol] 2024; Vol. 20 (29), pp. 2203-2212. Date of Electronic Publication: 2024 Jun 19.
DOI:	10.1080/14796694.2024.2349510
Abstrakt:	Aim: Characterize febrile neutropenia in the real-world and explore potentially modifiable risk factors. Patients & methods: Characteristics of patient presenting with febrile neutropenia after systemic cancer treatment were investigated, with a thorough evaluation of potential risk factors. Results: The rate of febrile neutropenia requiring hospitalization was comparable with clinical trials (mean absolute difference 2%, 95% CI: -1-4%; p = 0.29). The in-hospital mortality rate was 6%. Most cases resulted from low-risk regimens (50%) and 18.2% presented no apparent risk factors. 42.4% of patients presented modifiable factors potentially involved in the occurrence of febrile neutropenia. Conclusion: Febrile neutropenia rate in contemporary real-world evidence is comparable with clinical trials. Appropriate G-CSF administration and avoidance of potentially harmful drug-interactions represent potential areas for improvement.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu